Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PLYX by emailGet an email when PLYX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PLYX, unsubscribe in one click. Privacy
📣 What PLYX Says Is Next
fourth quarter of 2026 · “Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to evaluate PLX-200’s safety and efficacy in the fourth quarter of 2026.”
Company press release, Sep 1, 2026 · SEC filing
fourth quarter of 2026 · “Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the fourth quarter of 2026 with trial sites in the United States followed by other foreign jurisdictions.”
Company press release, Sep 1, 2026 · SEC filing
Q4 2026 · ““With SOTERIA on track to initiate in Q4 2026, his proven track record will be highly valuable as we execute the trial, advance of key clinical milestones, and deepen our engagement with the patients and families affected by lysosomal storage disorders.” Earlier in his career, Dr. Charlton spent over a decade in clinical practice as a board-certified pediatric endocrinologist.”
Company press release, Sep 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PLYX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLYX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.